CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today presented additional interim data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. The data were presented at the Chemotherapy Foundation Symposium being held in New York City. Data from pharmacodynamic measurements shown earlier this year provided preliminary evidence of clinical activity, and new results from the initial 28 patients in the first six dose cohorts demonstrate that ALN-VSP is generally well tolerated. The study has not yet reached a maximum tolerated dose (MTD) and the trial continues to enroll patients with dose escalation. Importantly, the safety results from this study provide a significant human experience database applicable to broader elements of the Alnylam systemic delivery pipeline, including ALN-TTR01, an RNAi therapeutic for the treatment of transthyretin-mediated amyloidosis (ATTR) which is also in a Phase I clinical trial.
